


Anticancer agent 55

| | |
|--------------------|---|
| Cat. No.: | HY-146433 |
| CAS No.: | 2408800-91-7 |
| Molecular Formula: | C ₂₈ H ₂₁ Br ₂ FN ₂ O ₂ |
| Molecular Weight: | 596.28 |
| Target: | Apoptosis |
| Pathway: | Apoptosis |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |



BIOLOGICAL ACTIVITY

| | | | | | | | | | | | | | | | | | | | |
|--------------------|--|------------|-------------------|----------------|----------|------------------|------|---------|---|------------|-------------------|----------------|----------------|------------------|-------------------------------|---------|--|------------|-------------------|
| Description | Anticancer agent 55 is a potent anticancer agent. Anticancer agent 55 shows anticancer activity via reducing the cell viability and cell migration in a dose-dependent manner. Anticancer agent 55 induces apoptosis. Anticancer agent 55 has the potential for the research of prostate cancer and breast cancer ^[1] . | | | | | | | | | | | | | | | | | | |
| In Vitro | <p>Anticancer agent 55 (compound 3h) (0-100 μM; 48 h) inhibits cell viability with IC₅₀s of 1.18 μM and 1.95 μM for PC-3, MCF-7 cells, respectively^[1].</p> <p>Anticancer agent 55 (0, 1, 3, 10 μM; 24 h) inhibits cell migration of PC-3 cells and MCF-7 cells in a dose-dependent manner^[1].</p> <p>Anticancer agent 55 (0, 1, 3, 10 μM; 12, 24 h) induces apoptosis by increases the caspase-3 activity and cleaved PARP levels^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>PC-3, MCF-7 cells</td> </tr> <tr> <td>Concentration:</td> <td>0-100 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>48 h</td> </tr> <tr> <td>Result:</td> <td>Significantly inhibited cell viability of PC-3, MCF-7 cells with IC₅₀s of 1.18 μM and 1.95 μM, respectively.</td> </tr> </table> <p>Apoptosis Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>PC-3, MCF-7 cells</td> </tr> <tr> <td>Concentration:</td> <td>0, 1, 3, 10 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>PC-3 for 12 h; MCF-7 for 24 h</td> </tr> <tr> <td>Result:</td> <td>Induced apoptosis by increased the caspase-3 activity in a concentration-dependent manner.</td> </tr> </table> <p>Western Blot Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>PC-3, MCF-7 cells</td> </tr> </table> | Cell Line: | PC-3, MCF-7 cells | Concentration: | 0-100 μM | Incubation Time: | 48 h | Result: | Significantly inhibited cell viability of PC-3, MCF-7 cells with IC ₅₀ s of 1.18 μM and 1.95 μM, respectively. | Cell Line: | PC-3, MCF-7 cells | Concentration: | 0, 1, 3, 10 μM | Incubation Time: | PC-3 for 12 h; MCF-7 for 24 h | Result: | Induced apoptosis by increased the caspase-3 activity in a concentration-dependent manner. | Cell Line: | PC-3, MCF-7 cells |
| Cell Line: | PC-3, MCF-7 cells | | | | | | | | | | | | | | | | | | |
| Concentration: | 0-100 μM | | | | | | | | | | | | | | | | | | |
| Incubation Time: | 48 h | | | | | | | | | | | | | | | | | | |
| Result: | Significantly inhibited cell viability of PC-3, MCF-7 cells with IC ₅₀ s of 1.18 μM and 1.95 μM, respectively. | | | | | | | | | | | | | | | | | | |
| Cell Line: | PC-3, MCF-7 cells | | | | | | | | | | | | | | | | | | |
| Concentration: | 0, 1, 3, 10 μM | | | | | | | | | | | | | | | | | | |
| Incubation Time: | PC-3 for 12 h; MCF-7 for 24 h | | | | | | | | | | | | | | | | | | |
| Result: | Induced apoptosis by increased the caspase-3 activity in a concentration-dependent manner. | | | | | | | | | | | | | | | | | | |
| Cell Line: | PC-3, MCF-7 cells | | | | | | | | | | | | | | | | | | |

| | |
|------------------|---|
| Concentration: | 0, 1, 3, 10 μ M |
| Incubation Time: | PC-3 for 12 h; MCF-7 for 24 h |
| Result: | Increased cleaved PARP levels in a dose-dependent manner in PC-3 and MCF-7 cells. |

REFERENCES

[1]. Seo Y, et al. Expansion of chemical space based on a pyrrolo[1,2-a]pyrazine core: Synthesis and its anticancer activity in prostate cancer and breast cancer cells. Eur J Med Chem. 2020 Feb 15;188:111988.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA